Colin Hill

Colin Hill

Colin Hill

CEO, Gene Network Sciences
Water Cove Award recipient (2010)

In his professional career, Colin is currently the Chairman of the Board of Fina Technologies, a subsidiary of Via Science, and Chairman and CEO of GNS Healthcare, a leading healthcare analytics company that matches drugs to patients in clinical trials and in patient care.   

A valued supporter of Accelerated Cure Project, Colin has helped to make introductions that have opened many doors for us and increased our understanding of how data-oriented approaches and technologies such as those developed by GNS can contribute to curing complex diseases like MS. He believes that technology combined with ACP’s data resources could significantly advance research findings in MS.

Colin serves on the boards of the New York Foundation for Science, Technology and Innovation (NYSTAR) and of a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease. In 2004, he was named to MIT Technology Review‘s TR100 list of the world’s top innovators under the age of 35. He graduated with a degree in physics from Virginia Tech and earned master’s degrees in physics from McGill University and Cornell University.